Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
Summary
PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Cognition, the Company or We) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions. More about Cognition and its pipeline can be found at https://cogrx.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.